440 related articles for article (PubMed ID: 12591750)
1. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
Borer JS; Fox K; Jaillon P; Lerebours G;
Circulation; 2003 Feb; 107(6):817-23. PubMed ID: 12591750
[TBL] [Abstract][Full Text] [Related]
2. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
Ruzyllo W; Tendera M; Ford I; Fox KM
Drugs; 2007; 67(3):393-405. PubMed ID: 17335297
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.
Tardif JC; Ponikowski P; Kahan T;
Eur Heart J; 2009 Mar; 30(5):540-8. PubMed ID: 19136486
[TBL] [Abstract][Full Text] [Related]
4. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group.
Frishman WH; Pepine CJ; Weiss RJ; Baiker WM
J Am Coll Cardiol; 1995 Aug; 26(2):305-12. PubMed ID: 7608428
[TBL] [Abstract][Full Text] [Related]
5. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study.
Tardif JC; Ponikowski P; Kahan T;
Int J Cardiol; 2013 Sep; 168(2):789-94. PubMed ID: 23138014
[TBL] [Abstract][Full Text] [Related]
6. Heart rate slowing versus other pharmacological antianginal strategies.
Diaz A; Tardif JC
Adv Cardiol; 2006; 43():65-78. PubMed ID: 16936473
[TBL] [Abstract][Full Text] [Related]
7. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study.
Sellier P; Broustet JP
Am J Cardiovasc Drugs; 2003; 3(5):361-9. PubMed ID: 14728070
[TBL] [Abstract][Full Text] [Related]
8. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
Tardif JC; Ford I; Tendera M; Bourassa MG; Fox K;
Eur Heart J; 2005 Dec; 26(23):2529-36. PubMed ID: 16214830
[TBL] [Abstract][Full Text] [Related]
10. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
Thadani U; Ezekowitz M; Fenney L; Chiang YK
Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina.
Amosova E; Andrejev E; Zaderey I; Rudenko U; Ceconi C; Ferrari R
Cardiovasc Drugs Ther; 2011 Dec; 25(6):531-7. PubMed ID: 21830063
[TBL] [Abstract][Full Text] [Related]
12. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
Sulfi S; Timmis AD
Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297
[TBL] [Abstract][Full Text] [Related]
13. Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.
Jedlickova L; Merkovska L; Jackova L; Janicko M; Fedacko J; Novakova B; Chmelarova A; Majernik J; Pella D
Adv Ther; 2015 Oct; 32(10):962-70. PubMed ID: 26525390
[TBL] [Abstract][Full Text] [Related]
14. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
DiFrancesco D; Camm JA
Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
Chaitman BR
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris.
Tendera M; Borer JS; Tardif JC
Cardiology; 2009; 114(2):116-25. PubMed ID: 19468225
[TBL] [Abstract][Full Text] [Related]
17. Selective and specific I(f) inhibition: new perspectives for the treatment of stable angina.
Fox K
Expert Opin Pharmacother; 2006 Jun; 7(9):1211-20. PubMed ID: 16732707
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
Borer JS; Tardif JC
Am J Cardiol; 2010 Jan; 105(1):29-35. PubMed ID: 20102886
[TBL] [Abstract][Full Text] [Related]
19. Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (Coat Core) in chronic stable angina.
Glasser SP; Ripa S; Garland WT; Weiss R; Nademanee K; Singh S; Bittar N
J Clin Pharmacol; 1995 Aug; 35(8):780-4. PubMed ID: 8522634
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris.
Thadani U; Zellner SR; Glasser S; Bittar N; Montoro R; Miller AB; Chaitman B; Schulman P; Stahl A; DiBianco R
Circulation; 1991 Dec; 84(6):2398-408. PubMed ID: 1959195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
